Your browser is no longer supported. Please, upgrade your browser.
Settings
OREX Orexigen Therapeutics, Inc. daily Stock Chart
OREX [NASD]
Orexigen Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.19 Insider Own0.10% Shs Outstand14.59M Perf Week-3.85%
Market Cap58.36M Forward P/E- EPS next Y-6.72 Insider Trans-5.20% Shs Float14.49M Perf Month-5.66%
Income-17.70M PEG- EPS next Q-1.18 Inst Own49.10% Short Float22.39% Perf Quarter128.57%
Sales24.80M P/S2.35 EPS this Y-65.10% Inst Trans-15.15% Short Ratio4.08 Perf Half Y12.36%
Book/sh5.03 P/B0.80 EPS next Y30.70% ROA-5.40% Target Price10.00 Perf Year-31.03%
Cash/sh5.20 P/C0.77 EPS next 5Y- ROE-65.80% 52W Range1.65 - 6.50 Perf YTD129.89%
Dividend- P/FCF- EPS past 5Y13.70% ROI-50.60% 52W High-37.69% Beta2.63
Dividend %- Quick Ratio3.80 Sales past 5Y81.80% Gross Margin85.00% 52W Low145.45% ATR0.30
Employees67 Current Ratio4.20 Sales Q/Q-30.00% Oper. Margin- RSI (14)48.40 Volatility5.78% 6.62%
OptionableYes Debt/Eq2.74 EPS Q/Q251.60% Profit Margin-71.60% Rel Volume0.15 Prev Close4.00
ShortableYes LT Debt/Eq2.74 EarningsMar 28 BMO Payout- Avg Volume795.12K Price4.05
Recom3.00 SMA20-3.99% SMA500.68% SMA20017.12% Volume48,581 Change1.25%
Mar-16-16Reiterated RBC Capital Mkts Sector Perform $1 → $0.60
Mar-16-16Downgrade Piper Jaffray Overweight → Neutral
Mar-16-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-29-16Downgrade RBC Capital Mkts Outperform → Sector Perform $5 → $1
Feb-29-16Downgrade JP Morgan Overweight → Neutral
Feb-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Dec-11-15Resumed BofA/Merrill Underperform
Dec-04-15Downgrade Wells Fargo Outperform → Market Perform
Nov-06-15Reiterated RBC Capital Mkts Outperform $9 → $5
Oct-06-15Reiterated Piper Jaffray Overweight $21 → $11
Mar-27-15Reiterated RBC Capital Mkts Outperform $10 → $14
Jan-23-15Initiated RBC Capital Mkts Outperform $10
Jan-10-14Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Outperform $10
Sep-21-11Upgrade JMP Securities Mkt Perform → Mkt Outperform $5
Feb-01-11Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-01-11Downgrade Canaccord Genuity Buy → Hold
Dec-03-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform
Jul-16-10Reiterated JMP Securities Mkt Outperform $16 → $13
Jul-16-10Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Mar-20-17 07:25AM  How These Drug Makers Stocks are Faring? -- Orexigen Therapeutics, United Therapeutics, DURECT, and SciClone Pharma PR Newswire
Mar-08-17 06:10AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-07-17 08:56PM  Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Year End 2016 Financial Results on March 28, 2017 PR Newswire
Feb-27-17 09:30AM  Biotech's Rise Shows No Sign of Slowing Down in 2017: Today's Reports on IntelliPharmaCeutics and Orexigen Therapeutics Accesswire
Feb-24-17 04:07PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fina +11.56%
Feb-17-17 08:56AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and -6.41%
Feb-09-17 07:27AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +12.66%
Feb-07-17 04:40PM  Orexigen Therapeutics to Speak at Upcoming Investor Conferences PR Newswire +9.31%
Feb-06-17 05:23PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jan-25-17 07:40AM  Orexigen Therapeutics Announces Spanish Launch of Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Partnership with Laboratorios Farmaceuticos Rovi, S.A. PR Newswire
Jan-12-17 06:08AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +5.94%
Jan-11-17 08:47AM  Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU -5.04%
Jan-10-17 09:13AM  Orexigen Therapeutics (OREX) Shares March Higher, Can It Continue?
08:55AM  Celgene Issues Preliminary 2016 Results, Lifts 2017 View
Jan-09-17 08:15AM  Alexion Blood Disorder Drug Gets Orphan Designation in U.S.
06:11AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-06-17 08:05AM  Orexigen Therapeutics Announces Publication of Contrave® (naltrexone HCl and bupropion HCl extended-release tablets) Real-World Study Results in "Obesity" PR Newswire -10.58%
Jan-05-17 07:50AM  Orexigen Therapeutics Highlights Key Business Priorities for 2017 PR Newswire +11.18%
Jan-04-17 12:15PM  Wednesdays Top 5 Biopharma Movers +64.25%
Jan-03-17 08:29PM  Orexigen Therapeutics Launches "Brains Behind Weight Loss," a Dynamic Patient Focused Campaign to Educate Consumers on the Role of the Brain in Weight Loss PR Newswire +18.97%
Dec-30-16 09:03AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events
Dec-23-16 01:56PM  15 Stocks With The Highest Forecast Sales Growth
Dec-21-16 12:43PM  ETFs with exposure to Orexigen Therapeutics, Inc. : December 21, 2016
Dec-20-16 06:08AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and +5.71%
Dec-19-16 08:10AM  Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Biologix FZCO for Contrave® (naltrexone HCl / bupropion HCl prolonged release) for Ten Countries in the Middle East PR Newswire -6.91%
07:40AM  Orexigen Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference 2017 PR Newswire
Dec-12-16 08:35AM  Should You Avoid Orexigen Therapeutics, Inc. (OREX)? at Insider Monkey -5.00%
Dec-09-16 12:32PM  ETFs with exposure to Orexigen Therapeutics, Inc. : December 9, 2016
Dec-08-16 07:25AM  Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Consilient Health Ltd. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in the UK and Ireland PR Newswire +5.43%
Nov-23-16 09:09AM  Edited Transcript of OREX earnings conference call or presentation 3-Nov-16 9:00pm GMT
Nov-16-16 04:15PM  Orexigen Announces Presentation of Data for OREX-1019, a Preclinical Candidate for the Treatment and Management of Drug Addiction PR Newswire
Nov-15-16 01:04PM  OREXIGEN THERAPEUTICS, INC. Financials
Nov-14-16 02:06PM  ETFs with exposure to Orexigen Therapeutics, Inc. : November 14, 2016
Nov-08-16 07:30AM  Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant for Contrave® (naltrexone HCl / bupropion HCl extended release) in Australia and New Zealand PR Newswire -5.02%
Nov-07-16 11:43AM  Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016
06:06AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Nov-04-16 04:41PM  Orexigen (OREX) Posts Narrower-than-Expected Loss in Q3
Nov-03-16 05:13PM  Orexigen beats 3Q profit forecasts -8.30%
05:00PM  Orexigen Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today
04:18PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:01PM  Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2016 PR Newswire
07:07AM  Q3 2016 Orexigen Therapeutics Inc Earnings Release - After Market Close
Nov-02-16 04:30PM  Orexigen Therapeutics to Present at 25th Annual Credit Suisse Healthcare Conference PR Newswire
Oct-31-16 01:58PM  ETFs with exposure to Orexigen Therapeutics, Inc. : October 31, 2016 -7.27%
Oct-21-16 09:00AM  Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2016 Financial Results on November 3, 2016 PR Newswire
Oct-17-16 04:11PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits
Oct-04-16 10:13AM  ETFs with exposure to Orexigen Therapeutics, Inc. : October 4, 2016
Sep-16-16 11:18AM  ETFs with exposure to Orexigen Therapeutics, Inc. : September 16, 2016
Sep-07-16 04:10PM  Orexigen Therapeutics to Speak at the Rodman & Renshaw 18th Annual Global Investment Conference PR Newswire -5.08%
Aug-31-16 11:41AM  ETFs with exposure to Orexigen Therapeutics, Inc. : August 31, 2016
09:11AM  Orexigen Stock Up on Commercialization Deal for Contrave
Aug-30-16 08:00AM  Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Canada for Contrave® (naltrexone HCl / bupropion HCl extended release) PR Newswire
08:00AM  Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Canada for Contrave® (naltrexone HCl / bupropion HCl extended release) CNW Group
Aug-15-16 10:41AM  ETFs with exposure to Orexigen Therapeutics, Inc. : August 15, 2016
Aug-12-16 11:26AM  Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
Aug-05-16 02:23PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report +6.84%
Aug-04-16 06:05PM  Orexigen reports 2Q loss +6.69%
05:00PM  Orexigen Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today
04:09PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:01PM  Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016 PR Newswire
07:07AM  Q2 2016 Orexigen Therapeutics Inc Earnings Release - After Market Close
Aug-01-16 08:31AM  Orexigen Completes Acquisition of All U.S. Rights to Contrave® and Launches U.S. Sales Organization PR Newswire
08:30AM  Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Laboratorios Farmaceuticos Rovi, S.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Spain PR Newswire
06:13AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Regulation FD Dis
Jul-29-16 01:45PM  ETFs with exposure to Orexigen Therapeutics, Inc. : July 29, 2016
Jul-21-16 04:10PM  Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2016 Financial Results on August 4, 2016 PR Newswire
Jul-19-16 12:57PM  ETFs with exposure to Orexigen Therapeutics, Inc. : July 19, 2016
Jul-12-16 07:03AM  Splits Calendar: Orexigen Therapeutics splits before market open today (1:10 ratio)
Jul-11-16 06:08AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of -11.11%
Jul-08-16 04:02PM  Orexigen Therapeutics Announces Stockholder Approval of All Proposals at 2016 Annual Meeting and Reverse Stock Split PR Newswire
Jul-05-16 04:09PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure
Jun-27-16 07:07AM  These 5 Stocks Under $10 Are Set to Soar Higher -8.89%
Jun-22-16 04:30PM  Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
Jun-09-16 09:42AM  Most Popular Healthcare Penny Stocks Among Hedge Funds at Insider Monkey -20.31%
08:58AM  Orexigen Stock Gains More than 50% on Markman Hearing
Jun-08-16 05:13PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E +52.38%
04:10PM  Orexigen Therapeutics Announces Promotions of Tom Cannell to COO and Jason Keyes to CFO PR Newswire
09:00AM  Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave® Patent Litigation PR Newswire
Jun-03-16 03:33PM  ETFs with exposure to Orexigen Therapeutics, Inc. : June 3, 2016
Jun-01-16 02:19PM  Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016
May-27-16 04:10PM  Orexigen Announces Upcoming Presentations at European Obesity Summit 2016 PR Newswire
09:07AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
09:00AM  Orexigen Therapeutics Founder and Former Chairman Eckard Weber Steps Down from Board PR Newswire
May-26-16 09:00AM  Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
May-23-16 08:46AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
08:30AM  Orexigen Appoints New Member of Board of Directors and Announces Senior Management Changes PR Newswire
May-05-16 04:50PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report -6.82%
01:16AM  Edited Transcript of OREX earnings conference call or presentation 4-May-16 9:00pm GMT
May-04-16 05:02PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
05:00PM  Orexigen Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today
04:51PM  Orexigen reports 1Q loss
04:01PM  Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016 PR Newswire
07:07AM  Q1 2016 Orexigen Therapeutics Inc Earnings Release - After Market Close
May-03-16 05:30PM  Orexigen Therapeutics to Speak at the Bank of America Merrill Lynch 2016 Health Care Conference PR Newswire
08:30AM  Orexigen Expands Commercial Leadership Team with Appointment of Healthcare Industry Veteran Brian Longstreet as Senior Vice President of Global Market Access and Development PR Newswire
May-02-16 08:30AM  Orexigen Announces South Korean Approval of Contrave® (naltrexone HCI and bupropion HCI Extended-Release) Monotherapy for Weight Management in Overweight or Obese Adult Patients PR Newswire
Apr-28-16 09:00AM  Orexigen Announces Upcoming Presentations at XIII International Congress on Obesity hosted by the World Obesity Federation PR Newswire
Apr-25-16 12:44PM  Penny Stocks To Watch: Four Top Small Cap Stocks on Monday April 25 Accesswire +6.82%
09:00AM  Orexigen Therapeutics Expands Commercial Capabilities with Appointment of Beth Eastland, Vice President of Sales, and Eight Additional New Employees PR Newswire
Apr-21-16 09:30AM  The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen Zacks
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products. The company offers Contrave for the treatment of obesity. It has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in the United States, Canada, and Mexico. The company's product, Contrave also approved under the brand name of Mysimba in Europe. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moglia Stephen A.VP, Chief Accounting OfficerDec 19Sale1.968001,5680Dec 21 12:11 PM